Cytomegalovirus (CMV) is a double‐stranded DNA virus which can be transmitted by blood
transfusion. Its seroprevalence in adults ranges from 40% to 100% depending on …

Cytomegalovirus (CMV) remains a major threat to the immunocompromised host.
immunocompromised patients results from reactivation of latent virus in the seropositive …

Traditionally, leukoreduction and selection of blood products from seronegative donors have
been used as alternative strategies to reduce the risk of transfusion-transmitted …

Background and Objectives Cytomegalovirus (CMV) is a significant pathogen transmissible
through blood transfusion that can have devastating effects on immunocompromised …

Cytomegalovirus (CMV) transmission remains a particular concern for immunocompromised
patients, such as those undergoing bone marrow transplantation or receiving chemotherapy …

Fittingly, our interest in the biology and prevention of transfusion-transmitted CMV infection
(TTCMV) seems to follow a similar course, with long phases of relative inactivity punctuated …

BACKGROUND Leukoreduced (LR) or cytomegalovirus (CMV)‐seronegative cellular blood
components are commonly used to reduce the risk of transfusion‐transmitted CMV infection …

BACKGROUND: Human cytomegalovirus (CMV) is considered to latently infect blood cells.
Transfusion‐transmitted infection (TT‐CMV) of immunocompromised patients occurs despite …

Background and Objectives Cytomegalovirus poses a risk to transfusion safety as its
transmission to an immunocompromised recipient may lead to significant clinical sequelae …

Transmission of human cytomegalovirus (CMV) via transfusion (TT‐CMV) may still occur
and remains a challenge in the treatment of immunocompromised CMV‐seronegative …